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Abstract 
Background: Surface enhanced laser desorption/ionization time-of-flight mass spectrometry 
(SELDI-TOF) is an approach to biomarker discovery that combines chromatography and mass 
spectrometry. We aimed to consider the efficacy of Bc1, Bc2, and Bc3 serum biomarkers on 
early detection of breast cancer (BC) in this study. 
Study Design: In this prospective study, 91 patients who were admitted to our hospital 
between January 2007 and July 2008 were included. Serum samples from 91 women were 
stored at -80 °C until use. The cancer group included 27 cases of BC. The benign breast 
disease  group  included  24  women  with  benign  breast  diseases  and  control  group  37 
age-matched apparently healthy women. The data obtained for these three groups of patients 
was worked out for each serum biomarker (Bc1, Bc2, and Bc3) by using SELDI-TOF indi-
vidually and compared with each other separately and evaluated statistically.  
Results: Bc2 possesses the highest individual diagnostic power. Bc2 was statistically signifi-
cant in comparison between the malignant disease group, control group and benign disease 
group. Bc1 was statistically significant in the malignant disease group compared to control 
group as well as in the benign disease group compared to control group. Thus Bc1, rather than 
showing malignant progression, it shows tumoral progression or inflammatory process. Bc3 
was found upregulated in all malignant cases; however, it was not statistically significant 
compared to the benign disease group or the control group.  
Conclusions: It has been shown that Bc2 profiles might be useful in clinical practice to im-
prove BC diagnosis. However none of the proteomics reach reasonable AUC values for the 
discrimination of the BC. Additional confirmation in larger and similarly-designed
 prospective 
studies is needed to consider of the efficacy of Bc1 and Bc2 in early diagnosis of the BC. 
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INTRODUCTION 
Breast  cancer  (BC)  is  the  most  common  cancer 
among women in Westernized populations. In France, 
41,000  new  cases  are  diagnosed  yearly  and  25%  of 
these women are below the age of 50 (1–4). BC has 
heterogeneous behavior and the frequency of metas-
tasis  in  regional  lymph  nodules  depends  on  tumor 
type (5).  
Mammographic  imaging  is  the  most  effective 
approach for diagnosing BC in women older than 50 




made in the resolution of these imaging techniques, 
tumors smaller than 5 mm usually go undiagnosed. 
Moreover,  as  dense  breast  tissue  decreases  the 
mammographic sensitivity in young women, the ef-
fectiveness  of  mammography  has  not  been  estab-
lished  (7).  Finally,  high-grade  tumors  cannot  be  di-
agnosed with 1 to 2 years of regular mammography 
imaging. For these reasons, new approaches should 
be developed in order to improve diagnosis of BC and 
to increase the overall and disease free survival rates 
of  patients  who  were  diagnosed  with  this  disease 
(8,9).  
The high heterogeneity of BC warrants multiple 
biomarkers for early diagnosis of the disease. Many 
studies  have shown that several proteins change  in 
cancer. These changes may cause measurable altera-
tions and secretion of marker proteins to body fluids. 
Among  the  available  serum  biomarkers,  the  most 
popular one is the cancer antigen (Ca). Ca 15.3 is used 
in monitoring BC and for early diagnosis of BC me-
tastases.  Ca  15.3  measurements,  however,  are  not 
useful for diagnosis; it does not provide benefits in 
therapeutic decision-making in patients with BC (10). 
It is therefore essential to discover new biomarkers to 
manage  different  stages  of  BC  development.  Bi-
omarkers may be promising in diagnosing develop-
ment or progress of the disease and monitoring the 
treatment. 
Briefly,  mass  spectrometry  and  2D  gel  electro-
phoresis  technology  coupled  with  advanced  bioin-
formatics (11) enhanced the capacity of characterizing 
new biomarkers (12). Surface-enhanced laser desorp-
tion/ionization  time-of-flight  (SELDI-TOF)  mass 
spectrometry  is  another  approach  that  integrates 
chromatography and mass spectrometry. SELDI-TOF 
is an appropriate method to monitor protein changes 
in  complex  cellular  extracts  or  body  fluids  (serum, 
plasma,  urea,  nipple  aspiration  material,  etc)  (13). 
Various  selective  chips  to  which  biomaterials  may 
stick are used. Each of the different chip surfaces grip 
a proteins sub-line analyzed by the TOF mass spec-
trometry. Several comparative studies have described 
marked  and  different  forms  of  protein  in  prostate, 
bladder,  breast,  melanoma,  and  ovarian  cancers 
(14–20). Li  et al.  (21)  should  be  congratulated  for  a 
valiant effort to validate 3 previously identified serum 
BC  biomarkers by  surface-enhanced  laser  desorp-
tion/ionization  time-of-flight mass  spectrometry 
(SELDI-TOF MS). They observed three serum peaks to 
distinguish BC patients from controls by SELDI-TOF. 
They  called  the  serum  breast  cancer  biomarkers  as 
Bc1, Bc2, and Bc3. The present study aims to evaluate 
the effectiveness of Bc1, Bc2 and Bc3 in the early diag-
nosis of the BC in a prospective clinical trial.  
METHODS 
Patients  
This  prospective  study  was  performed  in  Ata-
türk  Training  and  Research  Hospital  First  surgical 
department between January 2007 and July 2008. The 
patients who consented to be in the study and were 
between  18-75  years  of  age  were  included  in  the 
study. The patients were divided into three groups. 
Group 1: BC group, Group 2: Benign breast disease 
group,  and  Group  3:  Healthy  women  group.  The 
pathological diagnoses were based on excisional bi-
opsy or segmental mastectomy in group 1 and 2. The 
Healthy women group was the women who had no 
complaints about their breast and the mammography 
and ultrasound study were normal. The patients with 
diabetes  mellitus,  chronic  obstructive  pulmonary 
disease,  and  other  site  malignancy  were  excluded 
from the study. The patients who had chemotherapy 
or radiotherapy previously were also excluded from 
the study. The patients whose pathological result was 
ductal  carcinoma  in  situ  in  group  1  were  excluded 
from the study. The patients with metastatic and lo-
cally advanced BC (stage IIIA, IIIB, IIIC, and IV) were 
not included in the study. All women signed a con-
sent form before serum collection for this institutional 
review board (IRB)-approved study. Consent of sub-
jects and the ethics board of Izmir Ataturk Training 
and Research Hospital were obtained. Serum samples 
were obtained from the patients who were included in 
the study. Blood sampling was performed after sur-
gery  in  the  patients  who  were  underwent  surgical 
intervention (in group1 and 2). The serum samples in 
group 3 were obtained after the mammography and 
ultrasonography  examination.  Sera  collected  from 
these patients were stored in the laboratory of Izmir 
Hıfzısıhha Institute at -80°C. The blood samples were 
analyzed for Bc1, Bc2, and Bc3 serum proteins using 
SELDI-TOF analysis method. Results were compared 
within three groups and 3 biomarkers (Bc1, Bc2, and 




Blood samples  were collected before operation 
and cure, following 12 hours of fasting, in sitting po-
sition  in  8-ml  vacuum  tubes  containing  gel  (BD™ 
P100  Blood  Collection  System  for  Plasma  Protein 
Preservation). Samples were centrifuged at 1500 g for 
15 minutes to separate sera. Serum samples were di-
vided in 250 µL units and were stored at -80ºC until 




Serum Protein Profile Determination  
Immobilized  metal  affinity  capture  arrays 
(IMAC30) protein chips loaded with Cu2+ metal were 
used to profile proteins in serum analyses. The sam-
ples were loaded to defined locations using a biopro-
cessor.  IMAC  30  protein  chips,  with  50  µL  100mM 
CuSO4 on each sample, were incubated at room tem-
perature for 5 minutes. The samples were then rinsed 
with distilled water and washed with 200 µL binding 
solution (500mM NaCl, 100mM NaH2PO4/NaOH, pH 
7.0) three times for 10 minutes. All sera were first di-
luted  with  dilution  solution  (9  M  urea,  50mM 
Tris/HCl, pH 9.0,2 % (wv1) CHAPS) at the ratio of 5:1. 
Sera were then diluted again with binding solution at 
the ratio of 10:1 and were applied in 100 µL amounts 
in the wells on the chip. Protein chips on which the 
samples  were  loaded  were  kept  in  the  horizontal 
shaker for one hour (at 900 rpm and room tempera-
ture) to ensure protein binding. Chips were washed 4 
times with 200 µL binding solution (for 10 minutes 
each on horizontal shaker), rinsed with distilled wa-
ter, and then dried at room temperature. One µL Ma-
trix solution (50% saturated solution of sinapinic acid 
in  50%  acetonitrile,  0.5%  trifluoroacetic  acid)  was 
added to each well and dried at room temperature. 
One µL Matrix solution was added and dried again. 
Chips were loaded automatically PBS IIc SELDI-TOF 
(Ciphergen, Biosystems Inc., Fremont, CA, USA) de-
vice  for  “surface-enhanced  laser  desorp-
tion/ionization  time-of  flight  mass  spectrometry” 
SELDI-TOF-MS  analysis.  For  protein  mass  analyses 
the  spectra  were  collected  at  0–20  kDa  range.  192 
pulse rate, positive direction, and 220 intensity were 
used for laser application. For protein mass determi-
nation,  external  calibration,  pure  peptide  standards 
(All-in-one  peptide  molecular  mass  standard 
-Ciphergen  Biosystems,  Inc.)  were  used.  This  is  the 
same technique previously described by Li et al (21). 
Pathology 
The  pathological  specimens  were  evaluated  at 
the pathology laboratory of Atatürk training and re-
search hospital. In  malignant subjects, the most de-
scriptive block was selected for each subject and Es-
trogen receptor (ER) (Novocastra RT4-ER-6F11 7 ml, 
UK),  Progesterone  receptor  (PR)  (Neomarkers  RM 
9102-S,  USA),  P  53  (Dako  Clone  Do7;  Denmark),  c 
erbB-2 (Labvision Clone SP 3 7 ml USA), and the Ki 67 
proliferation  marker  (Dako  Clone  MIB1,  Denmark) 
were applied with the Strept–Avidin–Biotin method. 
PR, P 53 and materials used for Ki 67 prolifera-
tion  were applied after diluting at 1/100, 1/25 and 
1/75, respectively, since they were concentrated ma-
terials.  Diaminobenzidine  (DAB)  was  used  as  chro-
mogen material and Mayer’s hematoxyline was used 
as opposite staining.  
In  ER,  PR,  and  P53  evaluation,  the  percentage 
and intensity (+  weak, 2+moderate, 3+ intense) 
of nuclear staining were considered and calculated.  
Cerb  B–2  was  scored  at  4  levels  based  on  the 
membranous staining in invasive tumors:  
Score 0: No staining  
Score  1:  Stainings  not  surrounding  the  cell 
membrane, the presence of which are hardly detected 
and which are not completely membranous (+) 
Score  2:  Presence  of  moderate  staining  com-
pletely surrounding cytoplasmic membrane in at least 
10% of invasive carcinoma cells or presence of mem-
branous staining in less than 30% provided that the 
staining is intense (++) 
Score 3: Presence of intense staining surrounding 
the whole cytoplasmic membrane in at least 30% of 
invasive cells (+++) 
Scores 0 and 1 were accepted as negative, and 
score  3  as  positive.  The  tumors  with  score  2  were 
evaluated  with  fluorescence  in  situ  hybridization 
(FISH) method and accepted as positive if the result 
was correlated by FISH method. 
Ki 67 was calculated by counting the areas where 
the nuclear staining was the highest. 
Statistical Analysis  
Spectra data were transferred to a data processor 
and software capable of analyzing univariate statisti-
cal  analysis  (ProteinChip  Data  Manager  Software). 
Mass  calibrations  of  all  spectra  were  performed  in-
ternally  and  peak  intensities  were  normalized  ac-
cording to total ion flow. 
Peak aggregation and selection were performed 
by excluding the very low mass region (0-1500 Da) 
overlapping with single-photon absorptiometry (SPA) 
peaks. Each peak cluster was compared using the one 
way Mann-Whitney U test for inter-group compari-
sons and p values of the group were calculated. Sta-
tistical significance was set at p<0.05. Areas under the 
receiver-operator  characteristic  curve  (ROC)  (AUC) 
were calculated for each peak cluster. All peaks that 
present statistically significant difference in one-way 
statistical analysis were checked and confirmed until 
there were no incorrect peaks.  
RESULTS  
The  descriptive  characteristics  of  the  groups 
were showed in Table 1. The BC group included 27 
patients  (18  invasive  ductal  carcinoma,  6  invasive 
lobular carcinoma, and 3 mixed type breast carcino-
ma; age range 37–73; mean age 52.6). ER was positive 




B2 was positive in 8 (29.6%) patients with immuno-
histochemical analysis. Breast conserving surgery was 
performed on 16 (59.2%) patients and the remaining 
11 (40.8%) patients underwent modified radical mas-
tectomy. The benign breast disease group included 24 
patients, of whom 7 had fibrocystic disease, 3 lipoma, 
3  sclerosing  adenosis,  9  fibroadenoma,  1  breast  ab-
scess, and 1 fat necrosis (age range 21–57; mean age 
40). The third group (the control group) included 37 
healthy female subjects (age range 23–71; mean age 
39.1). 
Complex protein profiles of sera of 27 women 
with BC, 24 women with benign breast disease and 37 
healthy  women  were  obtained  by  SELDI-TOF  MS 
analyses using IMAC30-NI beams. The spectra were 
normalized. As was expected, peaks were identified 
at 4.3 (Bc1), 8.1 (Bc2) and 8.9 (Bc3) kDA. The results of 
protein profiles and the statistical differences between 
the groups were showed in Tables 2.  
Bc2 was found significantly higher in both the 
comparison of malignant and benign patients (Figure 
1) and malignant patients versus patients in the con-
trol  group  (Figure  2)  (p=0.002  and  p=0.003,  respec-
tively) (Table 2). The AUC values did not reach at 0.70 
for the Bc2 in the groups. Bc1 was statistically signif-
icantly higher in the comparison of malignant patients 
to those in the control groups, as well as in the com-
parison  of  benign  patients  and  those  in  the  control 
group (p=0.006 and p=0.015, respectively). The AUC 
values were below the 0.70 for Bc1 in all groups. Alt-
hough  Bc3  was  high  in  all  malignant  patients,  the 
comparison of the benign and control groups did not 
yield a statistically significant difference (p=0.098 and 
p=0.134, respectively).  
 
Table 1: Descriptive characteristics of the patients 






Number of patients  27  24  37 
Age       
  Range  37-73  21-57  23-71 
  Median  52.6  40  39.1 
Pathology         
  Invasive lobuler carcinoma  18    - 
  Invasive ductal carcinoma  6    - 
  Mixed type breast carcinoma  3    - 
  Fibrocystic disease  -  7  - 
  Lipoma  -  3  - 
  Sclerosing adenosis  -  3  - 
  Fibroadenoma  -  9  - 
  Breast abscess  -  1  - 
  Fat necrosis  -  1  - 
ER (+)  20 (74.0%)  -  -   
PR (+)  18 (66.6%)  -  -   
C-erb B2 (+)  8 (29.6%)  -  - 
Surgery       
  Excisional biopsy  0  24  - 
  Breast conserving surgery  16 (59.2%)  -  -    
  Mastectomy  11 (40.8%)  -  - 
 
 
Table 2: The marker levels in the groups. 
  Bc1 4300kDa  Bc2 8100 kDa  Bc3 8900 kDa 
Control (mean+sd)  162.44+95*  39.93+25  152.93+62 
Benign (mean+sd)  217.9+137  31.46+23  148.29+58 
Malignant (mean+sd)  250.24+167  97.65+101†  185.28+95 
*: Bc1 level is statistically lower in the control group than the others.  
†: Bc2 level is significantly higher in the malignant group tan the others. 
 
 





Figure 1. Comparison of subjects in the malignant and benign groups for Bc2 
 






Diagnosing  early-stage  BC  before  it  becomes 
symptomatic  provides  the  opportunity  to  achieve 
complete cure and reduces the mortality of BC. Un-
fortunately, the data pooled between 1992 and 1999 in 
the United States show that 63% of the BC patients go 
undiagnosed during the early-stage (22). Small lesions 
are frequently missed and may not be visible, even by 
mammography, particularly in young women and in 
those with dense breast tissue (23). Molecular markers 
that can potentially be used to identify small lesions 
that are invisible to imaging techniques could provide 
an opportunity to treat a neoplasm before it invades 
tissue. In particular, markers that could be detected 
during the ductal carcinoma in situ (DCIS) stage may 
prove useful, since 100% of women with BC who are 
diagnosed during the early stage may be treated.  
Most of the molecular-based approaches inves-
tigating methods for early diagnoses of BC have spe-
cific  targets  such  as  oncogenes,  tumor  suppressor 
genes, growth factors, tumor antigens, and other gene 
products.  These  approaches,  however,  have  poor 
sensitivities and specificities since none of them alone 
is useful for the majority of the BC and none of them is 
specific for cancer or breast tissues. No biomarker has 
been suggested to date for the early diagnosis of BC 
(24). Tumor markers approved by the American Food 
and Drug Administration (FDA) such as CA 15.3 and 
CA  27.29  are  recommended  only  for  monitoring  of 
advanced or recurrent breast cancers (25). 
Common “change patterns” associated with the 
disease status are identified using approaches that are 
based on genomics and proteomics instead of target-
ing a specific anomaly that may occur in a small sub-
group of patients. Both genomic and proteomic ap-
proaches  accumulate  multidimensional  data  which 
may  be  analyzed  by  multivariate  statistics  and  by 
powerful pattern algorithms. A possible regression in 
these approaches is not a direct result of correspond-
ing pathologies but it rather tends to explore the pat-
terns among multiple variables that may be the result 
of a pre-analysis of a specific series of sample. There-
fore, it is more possible to obtain high classification 
rates  in  single-centered  studies.  An  independent 
analysis of a separate series of sample pooled from 
different patient groups and hospitals is a method to 
evaluate the actual performance of these markers.  
Jinang Li, from the John Hopkins Hospital, is the 
first to explore proteomics in early diagnosis of BC, 
who  also  enabled  the  advance  of  proteomics  and 
conducted the first clinical trial in this field (26). In 
their first study in 2002, Li et al. investigated the 3 
serum biomarkers Bc1 (4,3 kDa), Bc2 (8,1 kDa), and 
Bc3 (8,9 kDa) using SELDI-TOF technology in a BC 
group and a non-cancer control group. While Bc1 did 
not yield a very significant result in this study, Bc2 
and Bc3 were found in increasing values. Bc3 had the 
highest independent diagnostic power (26). However, 
the patients in the study by Li et al. were categorized 
as  malignant  and  control  groups  and  women  with 
benign breast disease and health women were in the 
same  group.  No  statistical  subgroup  analyses  were 
performed in this study.  
In the present study, statistical analyses for Bc1, 
Bc2, and Bc3 were carried out individually in women 
with malignant disease, in those with benign breast 
disease  and  in  healthy  women;  that  is,  subgroup 
analyses were performed. According to the results of 
the present study, Bc2 had the highest independent 
diagnostic power. There were statistically significant 
differences between the subjects with malignant dis-
ease and those with benign disease as well as between 
subjects with malignant disease and the control group 
(healthy women). However the AUC values were not 
reaching at 0.70 for the Bc2 in the groups. Bc3 was 
high in all malignant patients but individual compar-
ison of Bc3 between malignant subjects and those with 
benign disease and between malignant subjects and 
healthy  controls  did  not  result  in  significant  differ-
ences.  The  most  interesting  finding  of  the  present 
study different from the three previous studies con-
ducted on this subject relates to Bc1, which yielded a 
statistically significant difference between the malig-
nant and control groups (p=0.006) as well as between 
the women with benign disease and the control group 
(p=0.015). Unfortunately again the AUC values were 
below the 0.70 for Bc1 in all groups. The relevance of 
this finding is that it was the result of the first sub-
group  analysis  for  these  biomarkers.  Bc1  should 
therefore be studied in terms of tumoral development 
and inflammatory response rather than malignancy.  
Another study by Mathelin et al. included a total 
of 89 patients. Bc1a and Bc1b defined by the authors 
corresponded  to  the  Bc1  and  Bc3a  and  Bc3b  corre-
sponded to Bc3 of Li. However, the order of efficacy in 
the  study  by  Mathelin  et  al.  was 
Bc1a>Bc1b>Bc3b>Bc3a (27). 
Li et al. conducted a study in cooperation with 
John Hopkins Milan National Cancer Institute which 
included 176 subjects. Similar to their first study, they 
identified significant differences for Bc3 and Bc2 (21).  
The  four  studies  including  the  present  study 
conclude  that  the  available  3  biomarkers  reflect  the 
malignant nature of the tumor rather than indicating 
tumoral progress, as presence of metastases or tumor 
diameters were not affected by the lymph node dis-




The results of the present study and the other 
three studies did not fully confirm each other. Several 
hypotheses may be suggested to explain these differ-
ences. First of all, Li’s study was a retrospective one 
and therefore samples might have been prepared and 
converted in different ways. In the present study, the 
samples  were  treated  and  processed  the  same  way 
and  were  frozen  at  most  one  hour  after  they  were 
collected. As in Li’s self-criticism in his evaluation of 
study results (21), the fact that the sera was frozen or 
stored for extended periods of time  might  have re-
sulted in changes in the protein content, affecting es-
pecially the results of Bc1. The present study and the 
study  by  Mathelin  et  al.  (27)  demonstrated  that 
freezing times longer than one hour results in modi-
fications of several protein peaks. Moreover, the sera 
used  in  the  present  study  were  frozen  only  once. 
Perhaps even more importantly, the samples  of the 
present study were completely free from hemolysis: it 
is  well-known  that  hemolysis  greatly  ruins  protein 
profiles. Another factor may be the differences in sta-
tistical analyses. Direct analyses on linear data were 
used in the present study and the study by Mathelin 
et al. (27). Li et al., on the other hand, used logarithmic 
transformation of peak intensity (25).  
The  most  important  point  is  that  the  present 
study performed subgroup analyses while Li et al. (26, 
21)  and  Mathelin  et  al.  (27)  did  not.  Their  control 
groups included women with benign breast disease 
and  healthy  women  together,  whereas  the  present 
study  examined  these  three  groups  separately. 
Alongside BC, broad studies are being performed on 
ovarian, prostate, colon, lung, pancreatic, and bladder 
cancer with proteomics with the SELDI-TOF method 
(28–37). 
Proteomics were listed among BC tumor mark-
ers recommendations first in the American Society of 
Clinical  Oncology  (ASCO)  2007  guidelines.  Further 
prospective studies were recommended in this field 
particularly with the SELDI-TOF method (38).  
In conclusion, it can not be said that proteomics 
studied with SELDI-TOF method for early diagnosis 
of BC is useful in the clinical practice. Bc2 had the 
highest independent diagnostic power on BC on the 
base of the p value. Bc1 did not yield statistical sig-
nificance in the comparison of malignant subjects and 
the control subjects, although a statistical significance 
was found in the comparison of benign subjects and 
the control group. Bc1 should therefore be studied in 
terms of tumoral development and inflammatory re-
sponse  rather  than  malignancy.  Although  Bc3  was 
high in all malignant subjects, the comparison of the 
benign and control groups did not yield a statistically 
significant difference. None of the proteomics reach 
reasonable AUC values for the discrimination of the 
BC.  However,  larger  prospective  studies  and  sub-
group analyses are needed on this subject to say that it 
can be used in the clinical practice. 
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